Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$114.27 USD

114.27
223,619

-0.78 (-0.68%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $114.34 +0.07 (0.06%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Does Masimo (MASI) Have the Potential to Rally 27.46% as Wall Street Analysts Expect?

The mean of analysts' price targets for Masimo (MASI) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Buy Stocks for August 27th

LYTS, PDS, STRL, MASI and DEC have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2024.

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Alcon's (ALC) Market Share Gains, New Launches Aid Growth

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.

Walgreens (WBA) Partners With BARDA to Boost Clinical Research

Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.

Masimo (MASI) Gets New Suitors for Its Consumer Business Sale

Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.

Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity

The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.

Labcorp (LH) Gains From New Collaborations Amid FX Issues

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma

New Strong Buy Stocks for August 9th

LSPD, CART, MASI, STRL and DKL have been added to the Zacks Rank #1 (Strong Buy) List on August 9, 2024.

What Makes Masimo (MASI) a New Buy Stock

Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.

Compared to Estimates, Masimo (MASI) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Masimo (MASI) Tops Q2 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.